The Molecular Analysis for Precision Oncology Congress 2025 (MAP) will bring together leading experts to explore the latest advances in cancer research, with a focus on deepening the understanding of disease mechanisms and improving prevention and response strategies. Key topics include the integration of artificial intelligence in diagnostics and therapy, as well as advances in immunotherapy and new developments in aging, cellular senescence, microbiome, and cancer metabolism – all of which contribute to the evolving landscape of precision oncology.

The congress will take place on site in Paris, France, from September 15-16, with no virtual option.

Selected Programs

• Data on the behavior of T cells analyze changes in the immune system during cancer development and provide insights to intercept the disease in the preliminary stage before it develops into an advanced form.
  • Related content: Abstracts 178O, 22MO; Educational event

• Insights into the use of spatial multi-omic mapping in certain breast cancers to investigate factors that influence ctDNA release and the transition from early stage to invasive disease.
  • Related content: Abstracts 126O, 179MO

• Insights into artificial intelligence in cancer research: from developing a computer model to detect early signs of cachexia in brain cancer patients, to creating AI-powered digital twins of tumors to improve treatment and outcomes in cancer of unknown origin (CUP).
  • Related content: Abstracts 1MO, 2MO

• Results of a study investigating how small genomic alterations are associated with extraordinary and unexpected responses to targeted therapies in patients with advanced solid tumors.
  • Related Content: Abstract 125O

• Keynote Lecture “Cancer Genomics and Mutational Processes” by Núria López-Bigas, 16 September 2025, 14:00 – 14:30 CEST

The abstracts will be published online as a supplement to ESMO Open . The titles of the abstracts can be viewed via the online program .

MAP is a joint initiative of Cancer Research UK (CRUK), Unicancer and the European Society for Medical Oncology (ESMO).

Editor: X-Press Journalistenbüro GbR

Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.